Search the Newsreel

Enbridge Inc. stock rises Friday, outperforms market

Enbridge Inc. (ENB) saw its stock rise by 0.16% to C$70.61 on Friday, outperforming the broader Canadian market where the S&P/TSX Composite Index fell by 0.08%. Despite this gain, the company's stock closed 12.4% below its 52-week high of C$80.65, achieved on May 22nd.

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Large proposed sale of 42.9M EAT shares disclosed in Form 144 filing

An affiliate of Brinker International (EAT) has filed a Form 144, signaling an intent to sell approximately 42.9 million common shares through Fidelity Brokerage Services LLC on the NYSE, with a proposed sale date of August 14, 2026. The filing also details restricted stock …

Seabridge Gold (NYSE:SA) Trading Up 6.1% - What's Next?

WaterBridge Infrastructure LLC (WBI) Stock Price, News, Quote & History

OXBRIDGE RE HOLDINGS Ltd Q2 2026: Revenue $368K, EPS $0.02— 10-Q Summary

OXBRIDGE RE HOLDINGS Ltd (OXBR) reported its second-quarter 2026 results, showing a return to profitability with $368K in revenue and $0.02 diluted EPS, compared to a net loss in the prior year. The company's financial performance was boosted by fee income from SurancePlus and …

Seabridge Gold (SA) Surges 3.87% to $33.41, Testing Key Resistance at $35.08 - Diamond Pattern

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (NASDAQ: BBIO). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst sentiment on the company is anything to go …

Cellebrite DI (NASDAQ:CLBT) Sees Unusually-High Trading Volume After Strong Earnings

Should You Continue to Hold ACHC Stock at an 18.17X P/E Valuation?

Acadia Healthcare Company, Inc.ACHC benefits from strong long-term demand for behavioral health services. The company is expanding its network through joint ventures, de novo facilities and bed additions. Shares of ACHC have surged 113.1% year to date, significantly outperforming the industry's 13.2% growth during …

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …

Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore

Fabric.AI, Inc. Common Stock (FABC) 10K Form and Latest SEC Filings 2026

This article provides an overview of Fabric.AI, Inc. Common Stock (FABC)'s SEC filings, highlighting that the company has submitted over 390 documents since 2017. It details the significance of these filings for investors, explaining various form types like 10-K, 10-Q, 8-K, and Form 4, …

Die Bristol-Myers-Squibb-Aktie profitiert von FDA-Zulassung und solider Prognose

CLBT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Cellebrite DI Ltd.

SueWallSt has initiated an investigation into potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT) following a significant drop in its share price. The investigation stems from Cellebrite's Q2 2026 revenue falling below analyst expectations and the company subsequently lowering its full-year 2026 …

Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cellebrite DI (CLBT) has come under fresh scrutiny after its August 13 Q2 2026 earnings report, guidance cut, and CEO transition, with Levi …

Brinker International, Inc. Stock 12‑Month Price Target Raised to $272, Implies 14% Upside

Brinker International, Inc. (EAT) has seen its average 12-month price target raised to $272 from $267.22, based on estimates from 18 analysts. This updated target suggests a potential upside of approximately 14% from its August 13 closing price. The consensus rating for EAT remains …

DYO BOYA FABRİKALARI SANAYİ VE TİCARET A.Ş.(DYOBY) Sorumluluk Beyanı (Konsolide) 13 Ağustos 2026

Seabridge Gold (NYSE: SA) gains $151.7M from spin-out, advances giant KSM project

Seabridge Gold reported strong financial results for the three and six months ended June 30, 2026, primarily due to a $151.7 million gain from the spin-out of its Courageous Lake Project into Valor Gold Corp. The company achieved a net income of $117.5 million …

BBOT Q1 2026 Earnings: Narrower-Than-Expected Loss Suggests Cost Control at Pre-Commercial Oncology Firm

Colliers International Group Stock Gains Momentum as Diversified Growth and Improving Real Estate Activity Support a Favorable Outlook

Brightcom Group Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

iFabric Corp. (TSX:IFAB) Shares Slide as Market Reassesses Valuation, Growth Expectations and Short-Term Risks

Brinker International (NYSE:EAT) Rating Lowered to "Neutral" at Northcoast Research

Northcoast Research downgraded Brinker International (NYSE:EAT) from "buy" to "neutral" despite the stock trading near its 52-week high and a positive quarterly revenue report. The company reported $1.54 billion in revenue, exceeding expectations, though EPS slightly missed consensus. Despite this downgrade, analyst sentiment remains …

Rubrik CTO Arvind Nithrakashyap Sells $3.0 Million Stock

Key Points The transaction involved the sale of 38,460 shares at a weighted average price of $79.19, totaling ~$3 million. This disposition reduced the executive's direct stake in the company by ~12%. The sale was executed through the exercise of 38,460 stock options, with …

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

Kolibri Global Energy Inc. Q2 2026 Earnings Call Summary

Kolibri Global Energy Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Operational Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …

Oxbridge Re Holdings Limited Q2 2026 Earnings Call Summary

Oxbridge Re Holdings Limited Q2 2026 Earnings Call Summary - Moby Strategic Evolution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …

Needham cuts Cellebrite stock price target on guidance reduction

Needham has lowered its price target for Cellebrite DI Ltd. (NASDAQ:CLBT) to $12.50 from $15.00, while maintaining a Buy rating. This adjustment follows Cellebrite's reduced fiscal 2026 guidance for annual recurring revenue and total revenue, alongside the appointment of Shiven Ramji as the new …

Fabrinet Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

British American Tobacco slides Friday, underperforms market

British American Tobacco PLC (BATS) shares fell 1.17% on Friday, closing at £42.14. This performance underperformed the broader market, as the FTSE 100 Index (UKX) saw a smaller decline of 0.21%. The company's stock is now 20.88% below its 52-week high.

iFabric Corp Stock Under Pressure After Q2: Is Growth Losing Its Earnings Momentum?

iFabric Corp.’s Q2 Sales Vault 65 Percent

Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu

BMS welcomes new multiple myeloma drug as generics batter current portfolio

Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …

China Everbright Water to Pay Interest on 2025 Medium-Term Notes After Interim Dividend